CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer by Seini Moimoi | Feb 27, 2024 | Portfolio News
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics by Seini Moimoi | Feb 13, 2024 | Portfolio News
Endogenex™ Receives IDE Approval to Initiate Pivotal Clinical Study by Seini Moimoi | Jan 30, 2024 | Portfolio News
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy by Seini Moimoi | Jan 25, 2024 | Portfolio News
Endeavor BioMedicines Successfully Completes Phase 2a Trial Of ENV-101 In Patients With Idiopathic Pulmonary Fibrosis by Seini Moimoi | Jan 24, 2024 | Portfolio News
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates by Seini Moimoi | Jan 4, 2024 | Portfolio News
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain by Seini Moimoi | Jan 3, 2024 | Portfolio News
Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease by Seini Moimoi | Dec 19, 2023 | Portfolio News
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease by Seini Moimoi | Dec 18, 2023 | Portfolio News
WelbeHealth Opens Bay Area PACE Center Serving Vulnerable Seniors by Seini Moimoi | Dec 13, 2023 | Portfolio News
